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ABSTRACT
Objective: Over 90% of neuroendocrine tumors (NETs) in Bulgaria were reported to arise in the gastrointes-
tinal tract. Our objective was to study the incidence and localization of the gastroenteropancreatic NETs, di-
agnosed for one year.
Methods: The present retrospective study explores the incidence and localization of the gastroenteropan-
creatic NETs, diagnosed and operated for one year period (during 2014) in UMHAT “Dr. Georgi Stranski”, 
Pleven. 
Results: Seven cases of gastroenteropancreatic NETs were diagnosed and treated for the studied period. 
Most common primary sites were: pancreas in 4 (57.14 %) cases and 2 in colon (28.57 %) cases. According to 
the morphological criteria, 2 (28.57 %) were well differentiated NETs, 3 (42.86 %) were moderately differen-
tiated, and 2 (28.57 %) were poorly differentiated NETs. One of them was mixed adenoneuroendocrine carci-
noma. All cases demonstrated immunoexpression of Chromogranin A and Synaptophysin in addition to the 
distinct neuroendocrine morphology. Distant site metastases were observed in 5 (71.43 %) cases.
Conclusion: According to our results, most of the gastroenteropancreatic NETs were well and moderately 
differentiated and located in pancreas. A considerable number of patients had distant metastasis at the time 
of diagnosis. The expression of Chromogranin A and Synaptophysin supported the morphological diagno-
sis of gastroenteropancreatic NET.   
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INTRODUCTION
 The frequency of the neuroendocrine tumors 
(NET) is increasing by 5.8 % per year1, mostly 
due to the improved diagnostic approaches. 
They are a heterogenic group of tumors that 
can develop in every organ of the human body, 
but are predominant in the pancreas and the 
gastrointestinal tract.1 Gastroenteropancreatic 
tumors can be found most often in the small 
intestines (30.8), rectum (26.3%), large intestine 
(17.6%), pancreas (12.1%) and appendix (5.7%).1 
Primary epidemiological information about 
the frequency of the neuroendocrine tumors 
in Bulgaria was collected in 2013. The initial 
information includes 127 patients with NET 
from the regions of Sofia, Varna and Pleven. 
98% of the tumors are with a localization in 
the gastrointestinal tract.  The small intestines, 
rectum and appendix are most affected, while 
the gut, stomach and pancreas are less affected. 
There are no specific symptoms with 
this type of tumors.2,3,4 NET are usually 
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diagnosed late because of their unpredictable 
biological  behavior.  50% of the cases are with 
metastases at the moment of diagnosing. In 
27% of the cases the metastases are distant, 
while in 23% the metastases are regional and 
because of that the possibilities for antitumor 
treatment are limited.3,4,5  Several universal 
plasma tumor markers are used for diagnosing 
NET with different primary localization. The 
isolated increase of any of them is insufficient 
for the diagnosing of NET without histological 
verification. Gastroenteropancreatic tumors 
show slow biological progress, but are with 
notable malignant potential. The bigger 
part of them are not active functionally. 
The immunohistochemical characteristic of 
NET includes expression of 3 basic markers: 
neuron specific enolase-cytosolic marker, 
synaptophysin - transmembrane glycoprotein, 
located in the presynaptic vesicles of the neurons 
and chromogranins-soluble acid glycoproteins, 
located in the matrix of the neurosecretory 
granules. Chromogranin A is a universal marker 
for the neuroendocrine tissue and it’s a precursor 
of pancreatostatin. Histological diagnosing 
requires obligatory immunohistochemical 
investigation which must include the basic 
markers: chromogranin A and synaptophysin. 
Immunohistochemical investigation for Ki-
67-nuclear cell marker for determination of 
the proliferative potential of the tumors is 
recommended as standard.
The purpose of our presentation is the 
study of the frequency and localization of the 
gastroenteropancreatic tumors, diagnosed and 
operated on at University Hospital- Pleven for 
the period of one year (2014).
MATERIALS AND METHODS
This is a retrospective study covering 
a period of one year. The patients included 
were operated on at the surgical clinics of the 
University Hospital - Pleven.
The patients in this study were operated 
on because of a tumor process of the colon, 
rectum and pancreas. Patients on whom an 
appendectomy was performed in the surgical 
clinics of the University Hospital - Pleven during 
2014 are included as well. All patients underwent 
immunohistochemical investigation of the 
tumor material stored in a paraffin block at the 
Clinic of Pathoanatomy - University Hospital 
– Pleven.
The following methods are used in this 
study: 1.) Clinical; 2.) Clinicopathologic; 3.) 
Immunohistochemical.
 1. Clinical Methods – information about 
the sex and age of the patients at the date of their 
operation is used.
2. Clinicopathologic Methods – the 
information about the histological type of the 
tumor, ТNM- classification is used.
3. Immunohistochemical Investigation. The 
criteria of the World Health Organization and 
the European Association for Neuroendocrine 
Tumors (ENETS) are used in this study 
of pathomorphological assessment of the 
gastroenteropancreatic tumors. They include 
immunohistochemical verification of the 
neuroendocrine origin of the tumor (Positive 
chromogranin A and/or Synaptophysin), staging 
by the requirements of the 7th edition of the 
pTNM classification, mitotic index and/or Ki-67 
proliferative index.
RESULTS
7 cases of patients with gastro-
enteropancreatic tumors were diagnosed and 
operated on at the University Hospital – Pleven 
in 2014. The tumors were most frequently 
located in the pancreas - 4 patients (57.14%). In 
2 patients (28.57 %) the rectum was affected and 
in 1 patient it was a case of adenoneuroendocrine 
tumor, the so-called MANEC. Female to male 
ratio is 7/6.  In 5 patients distant metastases were 
found.
DISCUSSION
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The frequency of the gastroenteropancreatic 
neuroendocrine tumors increases every year 
according to recent European investigations.1 
The knowledge about these tumors is still 
insufficient and they are diagnosed late. The 
prognosis for the gastroenteropancreatic NETs 
depends on several clinicopathologic indices 
and on the histological type of the tumor:
• Grade of differentiation, 
• Size of the tumor, 
• Metastases in the regional lymphatic 
nodules, 
• Stage of the disease. 
The criteria mentioned above are not always 
sufficient for a deep and objective assessment of 
the NETs. More precise and deeper investigation 
of the immunohistochemical indices is needed 
for the clarification of the biological behavior 
of these tumors. Effective predictive markers 
showing the susceptibility to concrete type of 
antitumor treatment must be found and effective 
diagnostic markers that help the diagnosis of the 
different histological types of NET are needed 
as well.
Our investigation shows increase in the 
frequency of gastroenteropancreatic NETs in 
Bulgaria. Our future task will be to discover 
which immunohistochemical indices could be 
used as prognostic and predictive markers for 
the prognosis and the therapeutic approach to 
these tumors.
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Table 1. Distribution of the gastroenteropancreatic NET for 2014 by age, sex, localization and histological type.
 Age Sex localization Diagnosis Grade of 
differentiation 
1. 64 Female Large intestine T4NxM1 Neuroendocrine neoplasm G2 
2. 44 Female Pancreas Neuroendocrine tumor G2 
3. 69 Female Rectum MANEC G3 
4. 56 Female Pancreas Neuroendocrine tumor G2 
5. 40 Female Rectum Neuroendocrine carcinoid G1 
6. 62 Male Pancreas Neuroendocrine carcinoma G3 
7. 60 Female Pancreas T3N1M0 Neuroendocrine carcinoma G1 
